Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD

References

• VogelmeierCFCrinerGJMartinezFJGlobal strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: gold executive summaryEur Respir J2017493170021428182564
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J200526221422216055868
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEEffects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPDChest2006129350951716537846
   PubMed Web of Science ®Google Scholar
• van NoordJAde MunckDRBantjeTAHopWCAkveldMLBommerAMLong-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropiumEur Respir J200015587888510853852
   PubMed Web of Science ®Google Scholar
• HughesADChenYHegdeSSDiscovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl) amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1′-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, batefenterol): first-in-class dual pharmacology multivalent muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)J Med Chem20155862609262225629394
   PubMed Web of Science ®Google Scholar
• CazzolaMLopez-CamposJLPuente-MaestuLThe MABA approach: a new option to improve bronchodilator therapyEur Respir J201342488588724081753
   PubMed Web of Science ®Google Scholar
• LipsonDABarnhartFBrealeyNOnce-daily Single-Inhaler triple versus dual therapy in patients with COPDN Engl J Med2018378181671168029668352
   PubMed Web of Science ®Google Scholar
• LipworthBKuoCRJabbalSCurrent appraisal of single inhaler triple therapy in COPDInt J Chron Obstruct Pulmon Dis2018133003300930319248
   PubMed Web of Science ®Google Scholar
• CelliBRMacNeeWATS/ERS Task ForceStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
   PubMed Web of Science ®Google Scholar
• QuanjerPHStanojevicSColeTJMulti-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equationsEur Respir J20124061324134322743675
   PubMed Web of Science ®Google Scholar
• WieldersPLLudwig-SengpielALocantoreNBaggenSChanRRileyJHA new class of bronchodilator improves lung function in COPD: a trial with GSK961081Eur Respir J201342497298123429913
   PubMed Web of Science ®Google Scholar
• ChowdhuryBASeymourSMMicheleTMDurmowiczAGLiuDRosebraughCJThe risks and benefits of indacaterol – the FDA’s reviewN Engl J Med2011365242247224922168640
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the shine studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• MahlerDAKerwinEAyersTFLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (Indacaterol/Glycopyrrolate) versus its Mono-components and placebo in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201519291068107926177074
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• HughesADJonesLHDual-pharmacology muscarinic antagonist and β2 agonist molecules for the treatment of chronic obstructive pulmonary diseaseFuture Med Chem20113131585160521942250
   PubMed Web of Science ®Google Scholar
• DonohueJFWorsleySZhuCQHardakerLChurchAImprovements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbationsRespir Med2015109787088126006754
   PubMed Web of Science ®Google Scholar
• JanssensWVandenbrandePHardemanEInspiratory flow rates at different levels of resistance in elderly COPD patientsEur Respir J2008311788317898020
   PubMed Web of Science ®Google Scholar
• MahlerDAWatermanLAGiffordAHPrevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhalerJ Aerosol Med Pulm Drug Deliv201326317417923025451
   PubMed Web of Science ®Google Scholar
• PrimeDGrantACSlaterALWoodhouseRNA critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol: pressurized metered dose inhaler, Diskus inhaler, Diskhaler inhaler, and Turbuhaler inhalerJ Aerosol Med1999122758410539710
   PubMedGoogle Scholar
• ChewNYChanHKIn vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis TurbuhalerJ Aerosol Med200114449550111791690
   PubMedGoogle Scholar
• GrantACWalkerRHamiltonMGarrillKThe ELLIPTA® dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregiversJ Aerosol Med Pulm Drug Deliv201528647448526372466
   PubMed Web of Science ®Google Scholar
• HamiltonMLeggettRPangCCharlesSGillettBPrimeDIn vitro dosing performance of the ELLIPTA® dry powder inhaler using asthma and COPD patient inhalation profiles replicated with the electronic lung (eLung™)J Aerosol Med Pulm Drug Deliv201528649850626372465
   PubMed Web of Science ®Google Scholar
• AltmanPWehbeLDederichsJComparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trialBMC Pulm Med201818110029898702
   PubMed Web of Science ®Google Scholar
• PrimeDde BackerWHamiltonMEffect of disease severity in asthma and chronic obstructive pulmonary disease on Inhaler-Specific inhalation profiles through the ELLIPTA® dry powder inhalerJ Aerosol Med Pulm Drug Deliv201528648649726372467
   PubMed Web of Science ®Google Scholar